The Sevoflurane, Isoflurane and Desflurane Market is
expected to reach USD 1.5 billion by 2022 in comparison to USD 1.2
billion in 2014. These three chemicals are inhalation agents and have been used
by anesthesiologists, nurse anesthetists, and anesthesiology assistants on a
consistent basis. They are very strong and cost less, with minimum damage to the
ozone layer.
Market Drivers
One of the primary factors, triggering expansion in the sevoflurane,
isoflurane and desflurane market includes cardiovascular and respiratory
diseases affecting the geriatric population. Rising cancer, orthopedic, spinal
and gastro-intestinal cases have also furthered the market. Cataract surgery is
a major contributor to the global market and will need a higher production of
these chemicals.
Growing accidents and emergency cases also add income to the inhalation
anesthesia market. Universal insurance coverage as well as constant
improvements in medical infrastructure also ensure the development of the
sevoflurane, isoflurane and desflurane market. These agents are administered to
patients prior surgery, making the induction of general anesthesia much
simpler.
A major factor hindering the market is the quantity of CO2 released
in the environment, leading to global warming. Actually, only about
5 percent of the gases are consumed by patients. The rest are released into the
atmosphere and make it unhealthy. The most practical solution for this problem
is the anesthetic recycling of products used during the administration of
general anesthesia.
Browse Details
of Report@ https://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry
Products Overview
Sevoflurane
Sevoflurane is one of the most commonly used volatile anesthetic agents.
It is administered to babies and children. Sevoflurane is ideal for patients
with asthma or sensitive air passages. But its side-effects include delirium
and agitation. It can be given quickly without the use of intravenous
instruments.
Sevoflurane would capture over 70% of the worldwide sevoflurane,
isoflurane and desflurane market by 2022. The agent is expected to exceed USD 1
billion by the same year. It’s widely utilized for being low-priced and
possessing therapeutic benefits.
Isoflurane
Isoflurane is a halogen ether utilized frequently by veterinarians. It is
administered intravenously, relaxes the muscles and reduces pain. Isoflurane
has also been used for inducing sleepiness for long durations during surgery.
It is expected to register a CAGR of about 10% by 2022.
Desflurane
Desflurane is a halogen ether used in general anesthesia. Its
effectiveness is one-fifth of isoflurane. Desflurane cannot be administered
orally and requires an electrically heated dispenser to distribute the vapor.
It is mostly administered to bariatric patients and in cases of surgeries
lasting for short durations.
Regional Overview
The United States has a large geriatric population. This has led the
region of North America to occupy the biggest share in the worldwide inhalation
anesthesia market in 2014. Surgical ambulatory and inpatient procedures are the
driving factors of North America.
Asia Pacific will experience the fastest growth by 2022. This is owing to
the rise of chronic diseases and need for better health infrastructure in the
region. Medical tourism combined with insurance coverage will play a huge role
in sustaining the growth of the sevoflurane, isoflurane and desflurane market.
Key Players
The market is currently dominated by AbbVie and Baxter International.
However, it can expect strong competition from manufacturers like
Lunan Pharmaceutical Group and Piramal Enterprises.
Piramal Enterprises currently has isoflurane and sevoflurane production
underway. It will manufacture generic desflurane by 2016. AbbVie has
sevoflurane and isoflurane under production. Baxter International is the only
one that manufactures all the three products.
Anesthesia has some unhealthy effects. The recycling companies of
Deltasorb Technologies and Anesthetic Gas Reclamation reprocess anesthesia
containers and gases from hospital vents. Rising investments by the
aforementioned players would also accelerate the sales of the sevoflurane,
isoflurane and desflurane market.
Related Reports
@
Doxorubicin
Market: Doxorubicin market is expected to witness a significant growth in the
developed regions due to the multiple incidences of cancer occurrence in these
regions.
About Us:
Hexa
Research is a market research and consulting organization, offering industry
reports, custom research and consulting services to a host of key industries
across the globe. We offer comprehensive business intelligence in the form of
industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan
Shaw
Hexa
Research
Felton
Office Plaza
6265
Highway 9
Felton,
California 95018
United
States
Phone:
+1-800-489-3075
Email:
sales@hexaresearch.com
Website
- https://www.hexaresearch.com
No comments:
Post a Comment